Acerus Pharmaceuticals Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASP.TO research report →
Companywww.aceruspharma.com
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis.
- CEO
- Edward Gudaitis
- IPO
- 2009
- Employees
- 14
- HQ
- Mississauga, ON, CA
Valuation
- Market Cap
- $2.77M
- P/E
- -0.06
- P/S
- -0.49
- P/B
- -0.08
- EV/EBITDA
- -0.74
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 127.05%
- Op Margin
- 778.56%
- Net Margin
- 857.88%
- ROE
- 310.28%
- ROIC
- 12769.05%
Growth & Income
- Revenue
- $-4,133,000 · -480.92%
- Net Income
- $-35,456,000 · -45.17%
- EPS
- $-4.61 · 72.40%
- Op Income
- $-32,178,000
- FCF YoY
- -6.41%
Performance & Tape
- 52W High
- $10.00
- 52W Low
- $0.28
- 50D MA
- $0.52
- 200D MA
- $2.08
- Beta
- 1.03
- Avg Volume
- 1.30K
Get TickerSpark's AI analysis on ASP.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ASP.TO Coverage
We haven't published any research on ASP.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ASP.TO Report →